SEC Form 4 · accession 0001567619-19-000415
Aptose Biosciences Inc. · APTOF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William G. Rice
Officer — Chair, President & CEO · Director
Period of report
Jan 2, 2019
Accepted (ET)
Jan 3, 2019 · 7:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882361
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $1.91 | Jan 2, 2019 | A | 400,000 | A | — | Jan 2, 2029 | Common Stock | 400,000 | 400,000 | D |
Explanation of responses
- F1The options vest as follows: 50% on the first anniversary of the grant with the remaining 50% to vest as follows: 1/3 on the second anniversary of the grant; 1/3 on the third anniversary of the grant; and 1/3 on the fourth anniversary of the grant.